Trial: 201911207

REPLATINUM: A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially with a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer

Phase

III (Cancer Control)

Principal Investigator

Morgensztern, Daniel

Disease Site

Lung

Learn more about this study at: clinicaltrials.gov